Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704623 | 0.83 | PTGS2 (0.39) | PTGS2PTGS1BRD4 | |
| SCHEMBL5377415 | 0.77 | PTGS2 (0.40) | PTGS2PTGS1CYP1A2CYP2C19MAPT | |
| SCHEMBL6846588 | 0.73 | PTGS2 (0.39) | PTGS2PTGS1CYP1A2CYP2C19MAPT | |
| SCHEMBL6846585 | 0.67 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL6844095 | 0.67 | MEN1 (0.39) | PTGS2PTGS1BRD4 | |
| SCHEMBL7612387 | 0.67 | PTGS2 (0.39) | PTGS2 | |
| SCHEMBL27454511 | 0.66 | PTGS2 (0.51) | PTGS2MAOALOXL2LOX | |
| SCHEMBL7617482 | 0.65 | PTGS1 (0.44) | PTGS2PTGS1MAPT | |
| SCHEMBL6742699 | 0.63 | NR3C1 (0.54) | PTGS2PTGS1MAOALOXL2LOX | |
| SCHEMBL6838945 | 0.61 | PTGS2 (0.39) | PTGS2PTGS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204341-A1 | Nr2b receptor antagonists for the treatment or prevention of migraines | ALLEN CHRISTOPHER (US) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204341-A1 | Nr2b receptor antagonists for the treatment or prevention of migraines | HTR1B, HTR2B, HTR1A | PTGS2 138/4885PTGS1 90/4885CYP1A2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.